Biocorp (PAR:ALCOR) said today that it inked a deal with pharma giant Sanofi (NYSE:SNY) to integrate its Mallya sensor into Sanofi’s diabetes management platform.
Issoire, France-based Biocorp’s Mallya is designed to clip to an injection pen to automatically log and transmit dosage data. The deal calls for Sanofi to pay Biocorp €4 million, or about $4.5 million, “to support related development activities,” Biocorp said.
Get the full story at our sister site, Drug Delivery Business News